Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.


NDAQ:GLUE - Post by User

Monte Rosa Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(250)
•••
Post by whytestockson Oct 28, 2024 12:45pm
22 Views
Post# 36285255

The MoBot Report

The MoBot Report
Just In: $GLUE The MoBot Report2024-10-28 12:33:06 ET DENVER, Colo., Oct 28, 2024 ( 247marketnews.com )- MoBot&#x2019;s recent alerts involved; Monte Rosa (NASDAQ: GLUE ), Novartis (NYSE: NVS ), Trump Media (NASDAQ: DJT ), Evoke Pharma (NASDAQ: EVOK ), Autonomix Medical (NASDAQ: AMIX ), and Bright...GLUE - The MoBot Report

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities